Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
34
datasets available to search
ShareScore release 0.9.0
Dataset results
34 results for “disease treatment modelling”
Modelling data for: Short-course combination treatment for experimental chronic Chagas disease
<p><span>Chagas disease, caused by the protozoan parasite <em>Trypanosoma</em> <em>cruzi</em>, affects millions of people in the Americas and across the world leading to considerable morbidity and mortality. Current treatment options, benznidazole (BNZ) and nifurtimox, offer limited efficacy and often lead to adverse side effects due to long treatment durations. Better treatment options are therefore urgently required. Here we describe a pyrrolopyrimidine series, identified through phenotypic screening, that offers a clear opportunity to improve on current treatments. In vitro cell-based washout assays demonstrate that compounds in the series are incapable of killing all parasites, however, combining these pyrrolopyrimidines with a sub-efficacious dose of BNZ can clear all parasites in vitro after five days. Importantly, these findings were replicated in a clinically predictive<em> in vivo</em> model of chronic Chagas disease, where five days of treatment with the combination was sufficient to prevent parasite relapse. Comprehensive mechanism of action studies, supported by ligand-structure modelling, show that compounds from this pyrrolopyrimidine series inhibit the Q</span><sub><span>i</span></sub><span> active site of <em>T. cruzi</em> cytochrome <em>b</em>, part of the cytochrome <em>bc1</em> complex of the electron transport chain. Knowledge of the molecular target enabled a cascade of assays to be assembled to evaluate selectivity over the human cytochrome <em>b</em> homologue. As a result, a highly selective and efficacious lead compound was identified. The combination of our lead compound with BNZ rapidly clears<em> T. cruzi</em> parasites, both <em>in vitro</em> and <em>in vivo</em>, and shows great potential to overcome key issues associated with currently available treatments. </span></p>
Noscapine treatment effect in transgenic mouse model of Alzheimer's disease
<p>Cerebrovascular dysfunction and neuroinflammation play key roles in the pathophysiology of Alzheimer’s disease (AD). The kinin-kallikrein system involving bradykinin receptor has been proposed at the nexus of beta-amyloid, vascular pathology and inflammation in patients with AD and in animal models. Here, we evaluated the effect of blocking the bradykinin receptors 1 and 2 by treatment with the bradykinin antagonist noscapine on cerebrovascular dysfunction, inflammation and amyloid pathology in a transgenic mouse model of amyloidosis. Transgenic arcAβ mice, and wild-type littermates of 14 months-of-age were either treated with noscapine (3 g/L, acidified drinking water) or received drinking water as control for three months (n = 8-11 per group). Arterial spin labeling magnetic resonance imaging showed alleviated regional hypoperfusion in noscapine-treated arcAb compared to control arcAb mice. Functional magnetic resonance imaging showed mitigated reduced regional cerebral vascular reactivity in noscapine-treated arcAb compared to control arcAb mice.</p>
Using Clinical Prediction Models to Improve Treatment for Patients With Chronic Obstructive Pulmonary Disease (COPD)
ClinicalTrials.gov study NCT05309356. IPD Sharing: YES. Countries: 1. Publications: 1.
Modelling data for: Short-course combination treatment for experimental chronic Chagas disease
Open the record for dataset details and reuse information.
Global Transcriptomic Analysis of Topical Sodium Alginate Protection Against Peptic Damage in An In Vitro Model of Treatment-Resistant Gastroesophageal Reflux Disease
<p>PA= pepsin + Acid; "Sham + PA" means "Pretreatment + Treatment"</p> <p><span>Breakthrough symptoms </span>are thought to occur in roughly half of <span>all </span>gastroesophageal reflux disease (GERD) patients despite maximal acid suppression (proton pump inhibitor, PPI) therapy. Topical alginates have recently been shown to enhance mucosal defense against acid-pepsin insult during GERD. We aimed to examine potential alginate protection of transcriptomic changes in a cell culture model of PPI recalcitrant GERD. Immortalized normal-derived human esophageal epithelial cells underwent pretreatment with commercial alginate-based anti-reflux medications (Gaviscon Advance or Gaviscon Double Action), a matched-viscosity placebo control, or pH 7.4 buffer (sham) alone for 1 minute, followed by exposure to pH 6.0+pepsin or buffer alone for 3 minutes. RNA sequencing was conducted, and Ingenuity Pathway Analysis was performed with a false discovery rate of ≤0.01, and absolute fold-change of ≥<span>1.3. Pepsin-acid exposure disrupted gene expressions associated with epithelial barrier function, chromatin structure</span>, carcinogenesis, and inflammation<span>. Alginate formulations demonstrated protection by mitigating these changes and promoting extracellular matrix repair, downregulating proto-oncogenes, and enhancing tumor suppressor expression. </span>These data suggest molecular mechanisms by which alginates provide topical protection against injury during weakly acidic reflux and support a potential role for alginates in prevention of GERD-related carcinogenesis.</p>
An Integrated Prenatal and Postnatal Treatment Model for the Treatment of Newborns With Critical Congenital Heart Disease
ClinicalTrials.gov study NCT06768008. IPD Sharing: NO. Countries: 1. Publications: 1.
Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON
ClinicalTrials.gov study NCT02098668. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Molecular Pathogenesis of Alzheimer's Disease Onset in a Mouse Model: Effects of Cannabidiol Treatment
GEO Series GSE304212. Mus musculus. 60 samples. Type: Expression profiling by high throughput sequencing.
Targeting Histone K4 Trimethylation for Treatment of Cognitive and Synaptic Deficits of Mouse Models of Alzheimer's Disease (RNA-seq)
GEO Series GSE179998. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Epithelial dysfunction is prevented by IL-22 treatment in a Citrobacter rodentium-induced colitis model that shares similarities with Inflammatory Bowel Disease
GEO Series GSE168806. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
Long-term Urolithin A treatment ameliorates disease pathology in Alzheimer's Disease mouse models [I]
GEO Series GSE212972. Mus musculus. 24 samples. Type: Expression profiling by array.
Long-term Urolithin A treatment ameliorates disease pathology in Alzheimer's Disease mouse models
GEO Series GSE214417. Mus musculus; Homo sapiens. 94 samples. Type: Expression profiling by array.
State-transition Modeling of Blood Transcriptome Predicts Disease Evolution and Treatment Response in Chronic Myeloid Leukemia (CML)
GEO Series GSE244990. Mus musculus. 298 samples. Type: Expression profiling by high throughput sequencing.
Sex differences in LCWE-induced model of Kawasaki Disease vascultitis and response to Anakinra treatment
GEO Series GSE141072. Mus musculus. 28 samples. Type: Expression profiling by high throughput sequencing.
Intravenous chaperone treatment of late-stage Alzheimer's disease (AD) mouse model affects amyloid plaque load, reactive gliosis and AD related genes
GEO Series GSE263166. Mus musculus. 12 samples. Type: Expression profiling by high throughput sequencing.
Human stem cell based models of neuronal migration provide insight into neurological disease pathogenesis and potential treatment
GEO Series GSE72994. Homo sapiens. 7 samples. Type: Expression profiling by high throughput sequencing.
Targeting Histone K4 Trimethylation for Treatment of Cognitive and Synaptic Deficits of Mouse Models of Alzheimer's Disease
GEO Series GSE180001. Mus musculus. 10 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing.
Small Vessel Diseases: Ultra-realistic Microstructure Computational Model to Refine Individual Treatment
ClinicalTrials.gov study NCT06159140. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Clinical Validation Study for Optimization of Anemia MAnagement in Hemodialysis Patients With End Stage Kidney Disease Using the Dialysis Anemia TReatmenT Model
ClinicalTrials.gov study NCT05936021. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Construction of Theoretical Model of Medical Treatment Behavior of Patients With Chronic Kidney Disease
ClinicalTrials.gov study NCT06175585. IPD Sharing: YES. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.